Information Provided By: 
Fly News Breaks for January 4, 2016
GRFS
Jan 4, 2016 | 08:54 EDT
As previously reported, Morgan Stanley downgraded Grifols to Underweight from Equal Weight. Analyst James Francescone continues to expect Grifols' plasma business to grow below market rates over the next several years due to ongoing pressure from market conversion to subcutaneous administration, which Grifols has no product offering. Additionally, the analyst said pipeline catalysts are scarce and valuation is stretched.
News For GRFS From the Last 2 Days
There are no results for your query GRFS
